Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzelkitug alone and with checkpoint inhibitor in advanced solid tumors
NL-OMON59303Phase 1Completed
- Sponsor
- Genentech
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzelkitug in Nonhematologic neoplasms (2 arms), sponsored by Genentech. Started Feb 2024; status: completed.
02
Drugs
enzelkitug
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59303.